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OBJECTIVES We sought to assess the incidence and clinical significance of elevated cardiac troponin I
(cTnI) after percutaneous coronary intervention (PCI).
BACKGROUND Elevated creatine kinase-MB (CK-MB) is prognostically important after PCI, but the
prognostic significance of elevated cTnI after PCI is uncertain.
METHODS In a prospective substudy of the Sibrafiban Versus Aspirin to Yield Maximum Protection
From Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) trials, which
randomized patients with acute coronary syndromes (ACS) to receive aspirin or sibrafiban, we
measured cTnI (positive,1.5 ng/ml) and CK-MB (positive,7 ng/ml) in 481 patients with
PCI. Samples were collected immediately before and at 0, 8 and 16 h after PCI and analyzed
by a core laboratory. The primary end point was the Kaplan-Meier estimate of death,
myocardial infarction or severe, recurrent ischemia at 90 days.
RESULTS Overall, 230 patients (48%) had elevated cTnI after PCI. Such patients underwent PCI
sooner and were more likely to have coronary stenting. Elevated cTnI was associated with
nonsignificantly higher risks of the primary end point (11.5% vs. 8.7%; p 0.15) and of death
(1.8% vs. 0.4%; p 0.4) and a significantly higher risk of death or infarction (10.6% vs. 4.2%;
p  0.005). This pattern was more pronounced for patients who became positive only after
PCI: primary end point, 20.7% vs. 10.1% for patients who remained negative after PCI (p 
0.05); death, 5.2% vs. 0% (p  0.02); death or infarction, 18.1% vs. 4.1% (p  0.007).
CONCLUSIONS Elevated cTnI, often observed after PCI in patients with ACS, is associated with worse
90-day clinical outcomes. This marker, therefore, is a useful prognostic indicator in such
patients. (J Am Coll Cardiol 2002;39:1738–44) © 2002 by the American College of
Cardiology Foundation
After percutaneous coronary intervention (PCI), about 20%
of patients develop elevated creatine kinase (CK) or its MB
isoform (CK-MB) (1). Such elevations have been associated
with increased risks for death, myocardial infarction (MI)
and repeat revascularization (1). A recent study by Stone et
al. (2) of 7,147 patients with systematically collected
CK-MB after PCI suggested that the relationship with
in-hospital death may be manifest only at higher CK-MB
levels. Compared with CK or CK-MB, the cardiac tro-
ponins are more specific biomarkers of myocardial necrosis
and may be more sensitive in detecting myonecrosis after
PCI. However, the prognostic significance of elevated
troponin levels after PCI has not been prospectively evalu-
ated (3).
We report the results of a prospective substudy within the
Sibrafiban Versus Aspirin to Yield Maximum Protection
From Ischemic Heart Events Post-acute Coronary Syn-
dromes (SYMPHONY) and 2nd SYMPHONY protocols,
designed to assess the incidence and clinical significance of
elevated cardiac troponin I (cTnI) after PCI.
METHODS
Study population. The SYMPHONY and 2nd SYM-
PHONY trials (4–6) randomized patients within seven
days after presentation with unstable angina or MI to
receive either an oral glycoprotein IIb/IIIa inhibitor, sibra-
fiban or placebo. In SYMPHONY, 9,233 patients were
randomly allocated to receive either aspirin 80 mg or
low-dose or high-dose sibrafiban twice daily for 90 days.
The 2nd SYMPHONY trial randomized 6,671 patients
to receive aspirin 80 mg, low-dose sibrafiban plus aspirin
80 mg, or high-dose sibrafiban twice daily for a final median
treatment duration of 90 days.
All North American patients enrolled in either trial who
underwent PCI after randomization were required by pro-
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tocol to have periprocedural serum samples drawn for
CK-MB analysis. In a prospective substudy, these samples
were also analyzed for cTnI. The troponin substudy was
approved by the institutional review boards or ethics com-
mittees of the participating hospitals.
In total, 15,904 patients were enrolled in the SYM-
PHONY trials, 8,056 in North America. Of North Amer-
ican patients, 1,547 (19%) underwent PCI, and 657 had
serum samples sent to the core biochemistry laboratory. A
total of 176 patients were excluded—17 had only prepro-
cedural samples, 6 had only an immediately postprocedural
sample, 24 had samples drawn outside the 24-h window
surrounding PCI, and 129 underwent PCI before random-
ization—leaving 481 patients who underwent PCI and had
samples drawn during the appropriate time window.
Sample collection and analysis. Samples were collected
within 1 h before PCI, immediately after PCI and at 8 h (6
to 10 h) and 16 h (12 to 20 h) after PCI. All samples were
prepared and stored locally at 70°C until shipped to the
core laboratory (University of Maryland), where they were
analyzed for CK-MB and cTnI using the Dimension
RxL/HM analyzer (Dade Behring, Glasgow, Delaware).
The analytical sensitivities for CK-MB and cTnI assays
were 0.5 ng/ml and 0.04 ng/ml, respectively. The manufac-
turer’s suggested upper cutoff levels for the diagnosis of
acute MI were considered positive for the primary analysis
(cTnI level 1.5 ng/ml and CK-MB level 7 ng/ml,
respectively). A secondary analysis was performed using
0.8 ng/ml as the cutoff level for positive cTnI.
Procedures and adjunctive medications. The decision to
perform angiography or revascularization was left to treating
physicians. All devices approved for PCI, including stents,
atherectomy and lasers, were permitted. All patients re-
ceived open-label aspirin the day of and day after PCI. After
stenting, patients in the aspirin groups received ticlopidine
250 mg twice daily for two to four weeks. In SYMPHONY,
patients in the sibrafiban groups who underwent stent
implantation initially had received placebo for two to four
weeks. After an interim safety analysis detected a higher-
than-expected rate of stent thrombosis in the low-dose
sibrafiban group, the protocol was amended to treat patients
in this group with ticlopidine 250 mg twice daily for two to
four weeks after stenting. In 2nd SYMPHONY, patients in
both sibrafiban groups received placebo for two to four
weeks. In all groups, study drug was continued without
interruption through the periprocedural period, unless ab-
ciximab or another intravenous glycoprotein IIb/IIIa inhib-
itor was used during PCI. In these cases, study drug was
held for 48 h after abciximab infusion (or for 8 h after
eptifibatide or tirofiban infusion).
End points. The primary end point for SYMPHONY was
the 90-day composite incidence of death (all-cause), myo-
cardial (re-)infarction or severe, recurrent ischemia (SRI)
requiring urgent revascularization. The time to this com-
posite end point was the primary end point in 2nd SYM-
PHONY. For this substudy, the primary assessment was the
relationship between postprocedural cTnI status (positive or
negative) and time to the 90-day composite of death, MI or
SRI after PCI. Secondary analyses included the relationship
of postprocedural cTnI status with the end points of death,
MI and their composite. The MI and ischemia end points
were used as defined and adjudicated by blinded central
events classification committees for the main trials (4–6).
The criteria for MI included: CK-MB above the upper limit
of normal after an ischemic event, 3 times the upper limit
of normal after PCI, 5 times the upper limit of normal
after bypass surgery or new, significant Q waves on electro-
cardiogram. In 2nd SYMPHONY, only the first MI and
first SRI episode after randomization were adjudicated. For
this analysis, adjudicated events were used unless a patient in
2nd SYMPHONY had suffered an event before PCI, in
which case investigator-reported events were used.
To eliminate the influence of positive cardiac markers
before PCI, we also assessed the impact of postprocedural
cTnI status on clinical outcomes after excluding patients
with positive or missing preprocedural CK-MB or cTnI
values, leaving only patients known to be preprocedural
cTnI-negative. Comparisons between preprocedural cTnI-
positive and preprocedural negative/postprocedural negative
and preprocedural negative/postprocedural positive groups
were also explored.
Statistical analysis. Continuous variables are summarized
as medians (25th, 75th percentiles), discrete variables as
percentages. Groups were compared using the likelihood-
ratio chi-square test for discrete variables and the Wilcoxon
rank-sum test for continuous variables. P values are pre-
sented for descriptive purposes; no adjustments were made
for multiple comparisons.
The occurrence of postprocedural end points is presented
in tabular form as Kaplan-Meier (KM) estimates (95%
confidence interval [CI]). Multivariable Cox proportional-
hazards modeling was performed with time to death or MI
as the dependent variable. Candidate variables used in the
models included: cTnI, age, gender, weight, creatinine
clearance, days from qualifying event to PCI, stent use, prior
MI, prior angina, elevated enzymes during qualifying event
and multivessel intervention. Two models were developed
Abbreviations and Acronyms
ACS  acute coronary syndromes
CI  confidence interval
CK-MB  creatine kinase-MB
cTnI  cardiac troponin I
HR  hazard ratio
KM  Kaplan-Meier
MI  myocardial infarction
PCI  percutaneous coronary intervention
SRI  severe recurrent ischemia
SYMPHONY  Sibrafiban Versus Aspirin to Yield
Maximum Protection From Ischemic
Heart Events Post-acute Coronary
Syndromes trial
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incorporating cTnI as a binary variable and cTnI as a
continuous variable. Kaplan-Meier survival curves were
constructed to compare event-free survival after PCI by
postprocedural cTnI status and were compared using the
log-rank chi-square test. A p value of0.05 was considered
statistically significant.
RESULTS
Among the 481 substudy patients, 230 (48%) had elevated
cTnI, and 137 (29%) had elevated CK-MB after PCI. A
strong correlation was present between the peak postproce-
dural CK-MB and cTnI levels (r  0.85, p  0.0001).
Postprocedural cTnI-positive patients less often had prior
angina and more often hypertension and positive cardiac
markers during the qualifying event (Table 1).
About 75% of interventions were elective, regardless of
cTnI status (Table 2). Postprocedural cTnI-negative pa-
tients more often had PCI for recurrent or refractory
ischemia, whereas postprocedural cTnI-positive patients
more often had PCI for (re)MI. Patients who were cTnI-
positive after PCI had intervention much sooner than
patients negative after PCI (median 3 vs. 11 days; p 
0.001). They were also significantly more likely to receive a
stent. Abciximab was used during PCI in 21% of cases;
patients treated with abciximab were more likely to have
elevated postprocedural cTnI (58% vs. 45%; p  0.02).
A nonsignificant trend was present for greater KM
estimates of the primary end point among patients with
positive postprocedural cTnI compared with patients who
were negative after PCI (11.5% vs. 8.7%; p  0.15) (Table
3). The hazard ratio (HR) (95% CI) for the primary end
point among patients with positive postprocedural cTnI was
1.49 (0.86 to 2.57). The KM estimates of death and SRI
were low and not significantly different, but the KM
estimate of MI alone was significantly higher among post-
procedural cTnI-positive patients (p  0.007). The KM
estimate of death or MI was significantly greater in patients
with elevated postprocedural cTnI (10.6% vs. 4.2%; p 
0.005). The KM estimates for each quartile of postproce-
dural cTnI elevation are listed in Table 4. With increasing
postprocedural cTnI levels, there were trends toward in-
creasing 90-day death and death or MI. Figure 1 shows the
timing of death or MI after PCI for patients with positive
and negative postprocedural cTnI.
When patients who had an end point MI 48 h after
PCI were removed from the analysis, those with elevated
Table 1. Baseline Characteristics by Substudy Inclusion and
Postprocedural Troponin I Status
Positive
Troponin I
(n  230)
Negative
Troponin I
(n  251)
Age (yrs) 56 (48, 67) 59 (50, 66)
Female gender (%) 21.3 27.5
Caucasian race (%) 86.5 87.6
Weight (kg) 86 (76, 99) 83 (74, 94)*
Current smoking (%) 37.8 37.5
Diabetes mellitus (%) 14.8 20.3
Family history of CAD (%) 66.5 55.0*
Hypercholesterolemia (%) 55.3 54.0
Hypertension (%) 47.4 56.2
Medical history
Angina (%) 43.2 52.2
Bypass surgery (%) 15.6 15.1
Infarction (%) 18.1 23.1
PCI (%) 18.3 17.7
Stroke (%) 2.2 1.2
Heart failure (%) 5.2 3.2
Chronic renal insufficiency (%) 0.4 0
Qualifying event
Elevated CK-MB (%) 92.1 78.0*
Elevated troponin I (%) 86.5 71.0*
Killip class III/IV (%) 1.3 2.8
Treatment assignment
Sibrafiban (%) 64.4 69.3
Placebo (%) 35.7 30.7
Multivessel CAD (%) 49.5 47.6
*p  0.05 vs. “Positive Troponin I.”
CAD  coronary artery disease; CK-MB  creatine kinase-MB; PCI 
percutaneous coronary intervention.
Table 2. Procedural Characteristics by Substudy Inclusion and
Postprocedural Troponin I Status
Positive
Troponin I
(n  230)
Negative
Troponin I
(n  251)
Indication
Elective (%) 73.9 76.9
Recurrent or refractory ischemia (%) 13.5 20.3
Abrupt closure (%) 1.7 0.4
Hemodynamic instability (%) 0 0.4
(Re)infarction (%) 10.9 2.0*
Days, qualifying event to procedure 3 (2, 5) 11 (5, 32)*
Multivessel intervention (%) 10.0 15.5
Target vessel
Left anterior descending (%) 36.5 41.4
Left circumflex (%) 25.7 30.7
Right coronary (%) 39.1 37.1
Left main (%) 1.3 2.4
Saphenous vein graft (%) 7.0 3.6
Type intervention
Angioplasty (%) 92.2 90.4
Stent (%) 87.8 77.3*
Atherectomy or laser (%) 4.5 4.0
Abciximab use (%) 26.1 17.1*
Angiographic success† (%) 91.3 86.1
*p  0.05 vs. “Positive Troponin I”; †diameter stenosis  50% after intervention, for
all attempted lesions.
Table 3. Kaplan-Meier Estimates (95% Confidence Interval) of
90-Day Events by Postprocedural Troponin I Status
Positive
Troponin I
(n  230)
Negative
Troponin I
(n  251) p Value
Death 1.8% (0.0–3.5) 0.4% (0.0–1.3) 0.4
MI 8.9% (5.2–12.6) 3.7% (1.2–6.6) 0.007
Severe recurrent ischemia 1.8% (0.0–3.5) 4.5% (1.7–7.2) 0.2
Death or MI 10.6% (6.6–14.6) 4.2% (1.5–6.9) 0.005
Any of these 11.5% (7.3–15.7) 8.7% (4.9–12.4) 0.2
MI  myocardial infarction.
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postprocedural cTnI still had a significantly higher KM
estimate of 90-day death or MI (7.8% vs. 3.7%; p  0.04).
Assessing clinical outcomes using a cTnI cutoff of
0.8 ng/ml, more patients were cTnI-positive after PCI
(57%), but otherwise the results were similar. Likewise, in
an analysis stratified by type of PCI (elective vs. nonelec-
tive), the troponin effect remained statistically significant
(p  0.003), and, in a Breslow-Day test, the p value was
0.571, suggesting that the association of cTnI with outcome
is not significantly different for elective and nonelective
patients.
After excluding patients with positive or missing prepro-
cedural cTnI values, postprocedural cTnI was elevated in 39
(26%) of 151 preprocedural cTnI-negative patients. The
pattern of increased risk among patients with new positive
cTnI after PCI was similar to that in the primary analysis
(Fig. 2). Among patients with new elevations of cTnI after
PCI, that is, those who were known to be cTnI-negative
before the procedure, the HR for 90-day death or MI was
4.3 (1.4 to 13.5) compared with 2.7 (1.3 to 5.4) for the
entire substudy cohort. Further, the HR for patients known
to be positive before the procedure was similar (2.4 [0.8 to
7.0]). Estimated 90-day death or MI rates were 6.1% for
patients with negative preprocedural cTnI who remained
negative after PCI, 18.1% for patients with negative pre-
PCI cTnI who became positive after PCI and 9.0% for
pre-PCI cTnI-positive patients.
In multivariable models including cTnI as either a con-
tinuous or binary variable, cTnI independently predicted
time to death or MI: HR 1.02 (1.01 to 1.03), p  0.0001
when cTnI was continuous and 3.0 (1.5 to 6.1), p  0.003
when cTnI was binary. The only other variables indepen-
dently associated with death or MI were previous MI (HR
2.1 [1.0 to 4.2], p  0.045) and history of angina (HR 2.3
[1.1 to 4.9], p  0.03).
DISCUSSION
This prospective substudy of the SYMPHONY trials con-
firms that cTnI is often elevated after PCI and that this is
an important predictor of later cardiac events. Nearly half of
all substudy patients had elevated cTnI after intervention.
Table 4. Kaplan-Meier Estimates (95% Confidence Interval) of 90-Day Events by
Postprocedural Troponin I Quartiles
TnI < 0.18
(n  120)
TnI 0.19–1.3
(n  120)
TnI 1.4–5.6
(n  121)
TnI > 5.6
(n  120) p Value
Death 0.0% (0.0–0.0) 0.9% (0.0, 2.6) 0.0% (0.0–0.0) 3.4% (0.1–6.6) 0.08
Death or MI 1.8% (0.0–4.2) 6.5% (1.8–11.3) 8.5% (3.5–13.6) 11.8% (6.0–17.6) 0.05
Death, MI or severe
recurrent ischemia
6.7% (1.8–11.5) 11.1% (5.1, 17.1) 9.3% (4.1, 14.6) 12.6% (6.6–18.6) 0.55
MI  myocardial infarction; TnI  troponin I.
Figure 1. Kaplan-Meier curve for freedom from death or myocardial infarction (MI) after percutaneous coronary intervention, by postprocedural troponin
status. cTnI  cardiac troponin I.
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These patients were at significantly increased risk for death
or MI at 90 days. The increase in risk is of similar
magnitude to that observed previously for postprocedural
CK-MB elevations.
Troponins and risk for cardiac events. The cardiac tro-
ponins are highly sensitive and specific in detecting myo-
necrosis. In patients presenting with acute coronary syn-
dromes (ACS), elevated troponin is associated with
significantly higher mortality (7,8). However, the prognos-
tic value of troponins after PCI has not been well estab-
lished. Prior studies have reported elevated post-PCI tro-
ponin in up to 45% of patients (9–17). Bertichant et al. (16)
found that troponin was elevated in 18% to 21% but found
no association between cTnI status and clinical outcomes at
a median 16 months after PCI. Fuchs et al. (17) recently
analyzed 1,129 patients undergoing PCI, of which 31% had
elevated cTnI after intervention. These patients had higher
rates of death, MI and target-lesion revascularization during
initial hospitalization, but there was no association between
cTnI positivity and late (up to eight months) clinical events.
To our knowledge, our report represents the first large,
prospective study to measure troponin levels before and after
PCI using a standardized assay in a core biochemical
laboratory and to systematically follow patients for clinical
events up to 90 days after PCI. Overall, postprocedural cTnI
was elevated in 48% of patients. After excluding those with
positive or unknown preprocedural cTnI, 26% had an
elevated postprocedural cTnI, consistent with prior studies
(12,16,17). We found that patients with positive postpro-
cedural cTnI had significantly higher 90-day rates of MI
and the composite of death or MI. This difference persisted
even after excluding patients with end point MI within 48 h
after the procedure from the analysis. There also was a trend
toward greater mortality in postprocedural cTnI-positive
patients, especially among patients with new postprocedural
cardiac marker elevations.
Potential mechanisms for post-PCI troponin elevation.
As with CK-MB, the pathophysiologic mechanism for
elevated cTnI after PCI is unclear. Potential mechanisms
include necrosis or ischemia from prolonged balloon infla-
tions, transient abrupt closure, distal embolization and
side-branch occlusion. Bertichant et al. (16) showed that
elevated postprocedural cTnI correlated most closely with
long balloon-inflation times and was not associated with
side-branch occlusion or other procedural complications.
Talasz et al. (9) found that, of 16 patients without side-
branch occlusion, none had elevated cTnT after interven-
tion, but three of five patients with side-branch occlusion
did show such elevations.
Coronary stents may increase the frequency of minor
myonecrosis by occlusion of small side-branches, increased
distal embolization or both. La Vecchia et al. (12) found
higher peak cTnI levels after stenting compared with a
matched cohort undergoing angioplasty; the difference
mainly reflected the occurrence of minor side-branch occlu-
sion. Two other studies have found no difference in the
incidence of cTnI elevation after stenting (16,17). In our
analysis, patients who underwent coronary stenting were
more likely to have elevated cTnI afterward than were
patients who did not (51% vs. 33%; p  0.002). These
findings must be interpreted cautiously because patients
with high-risk angiographic characteristics, dissection or
Figure 2. Unadjusted hazard ratios and 95% confidence intervals for the risk of events 90 days after percutaneous coronary intervention by postprocedural
cardiac troponin I (cTnI) status. Hazard ratios are depicted for the primary analysis population (n 481) and for patients with negative preprocedural cTnI
(n  151). CK-MB  creatine kinase-MB; MI  myocardial infarction; SRI  severe recurrent ischemia.
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suboptimal results would more likely undergo stenting.
However, because about 80% of the patients in the SYM-
PHONY trials received a stent, this is less likely to be a
major explanation in our study.
Even small CK-MB elevations (one to three times the
upper limit of normal) after PCI are associated with higher
six-month death or MI (18–20). Our findings indicate that
elevations in cardiac troponins, the most sensitive markers
of cardiac myonecrosis, also are significantly associated with
the risk of death or MI. Periprocedural myonecrosis appears
to represent a spectrum of risk. Large elevations in CK-MB
after PCI are associated with the worst clinical outcomes,
but even small CK-MB or cTnI elevations are associated
with adverse outcomes.
Study limitations. The sample size of the study was small
with low event rates, particularly for death and SRI.
Therefore, the estimates of association may be somewhat
unstable. However, the consistency of the point estimates in
both the overall analysis and in patients with newly positive
troponin after PCI favoring an increased risk for each end
point in troponin-positive patients is reassuring.
Although we report an association between postproce-
dural cTnI elevation and 90-day outcomes, a causal rela-
tionship cannot be inferred from these data alone. Discus-
sion continues about whether elevated postprocedural
CK-MB is merely a marker of vessel or plaque characteris-
tics predisposing to recurrent plaque rupture or whether the
myonecrosis that occurs during PCI relates directly to
long-term outcomes. Detailed angiographic data such as
lesion morphology were not collected in the SYMPHONY
trials and, therefore, could not be included in the multiva-
riable model. Glycoprotein IIb/IIIa inhibitors have been
shown to reduce both the incidence of elevated CK-MB
after PCI and the risk of death or MI, suggesting a causal
relationship between periprocedural cardiac markers and
clinical outcomes (21). The impact of glycoprotein IIb/IIIa
inhibitors on postprocedural troponin release has not been
studied. In our study, abciximab was used more often in
postprocedural cTnI-positive patients. This difference likely
reflects the more frequent use of abciximab in patients with
high-risk clinical and angiographic characteristics, such as
intracoronary thrombus, or in “bail-out” situations after
procedural complications have developed.
Troponin can remain elevated for 7 to 10 days (7). As a
result, a substantial proportion of patients with ACS in this
analysis had elevated preprocedural cTnI. In such cases,
adverse long-term prognosis may relate more to the recent
ACS than to elevated cTnI after PCI. However, the
association between elevated cTnI after PCI and the risk of
death or MI was even stronger when considering only
patients with documented negative preprocedural cardiac
markers. This suggests that the prognostic association of
postprocedural cTnI elevation with 90-day outcomes is not
driven by risk related to preprocedural ischemic events with
resultant cTnI elevation. Furthermore, the comparison of
patients known to be preprocedural cTnI-positive, reflecting
elevations from prior ischemic events, with those known to
be preprocedural cTnI-negative who then had new postpro-
cedural cTnI elevation suggests that the risk for subsequent
events is at least as great, if not greater, among patients with
new post-PCI cTnI elevations as it is among those with
elevations due to ischemic events who then undergo PCI.
In this study, follow-up was available only up to 90 days
after PCI. Further studies are required to determine the
relationship between postprocedural troponin positivity and
long-term clinical outcomes. This analysis was limited to
patients undergoing PCI within 90 days of ACS. Such
patients are at higher risk for ischemic events during and
after PCI. Whether these findings can be extrapolated to
patients with stable coronary disease undergoing PCI re-
quires further study.
Conclusions. Cardiac troponin I often is elevated after
PCI, with positive results in 25% to 50% of patients.
Elevated cTnI after PCI is strongly associated with in-
creased 90-day risks of MI and the composite of death or
MI, even after adjustment for baseline characteristics, pro-
cedural variables and preprocedural marker status. The
prognostic value of cTnI after PCI is consistent with and
similar to that of CK-MB. Further study of the pathophys-
iology of troponin elevation after PCI, its relationship to
adverse outcomes and measures to alter the pathophysiology
is warranted.
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